306 related articles for article (PubMed ID: 32479127)
1. Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals.
Cirrincione LR; Senneker T; Scarsi K; Tseng A
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):565-582. PubMed ID: 32479127
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
Yager JL; Anderson PL
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
Meemken L; Hanhoff N; Tseng A; Christensen S; Gillessen A
Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
[TBL] [Abstract][Full Text] [Related]
4. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.
Radix A; Sevelius J; Deutsch MB
J Int AIDS Soc; 2016; 19(3 Suppl 2):20810. PubMed ID: 27431475
[TBL] [Abstract][Full Text] [Related]
5. Which U.S. States' Medicaid Programs Provide Coverage for Gender-Affirming Hormone Therapy and Gender-Affirming Genital Surgery for Transgender Patients?: A State-by-State Review, and a Study Detailing the Patient Experience to Confirm Coverage of Services.
Zaliznyak M; Jung EE; Bresee C; Garcia MM
J Sex Med; 2021 Feb; 18(2):410-422. PubMed ID: 33422448
[TBL] [Abstract][Full Text] [Related]
6. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
[TBL] [Abstract][Full Text] [Related]
7. Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.
Esposito I; Labarga P; Barreiro P; Fernandez-Montero JV; de Mendoza C; Benítez-Gutiérrez L; Peña JM; Soriano V
Expert Opin Drug Saf; 2015; 14(9):1421-34. PubMed ID: 26212044
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions in HIV-infected patients treated for hepatitis C.
Soriano V; Labarga P; Fernandez-Montero JV; Mendoza C; Benítez-Gutiérrez L; Peña JM; Barreiro P
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):807-816. PubMed ID: 28689442
[TBL] [Abstract][Full Text] [Related]
9. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
[TBL] [Abstract][Full Text] [Related]
10. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition.
Nguyen HB; Chavez AM; Lipner E; Hantsoo L; Kornfield SL; Davies RD; Epperson CN
Curr Psychiatry Rep; 2018 Oct; 20(12):110. PubMed ID: 30306351
[TBL] [Abstract][Full Text] [Related]
11. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
Burgess S; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
Ann Pharmacother; 2015 Jun; 49(6):674-87. PubMed ID: 25770114
[TBL] [Abstract][Full Text] [Related]
12. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV.
Martinez CA; Rikhi R; Fonseca Nogueira N; Pester MS; Salazar AS; Ashinne B; Aguilar N; Melara A; Porras V; Parker M; Mendez A; Cyrus E; De Santis JP; Jones DL; Brown TT; Hurwitz BE; Alcaide ML
LGBT Health; 2023; 10(8):576-585. PubMed ID: 37459150
[No Abstract] [Full Text] [Related]
15. Prevalence of and factors associated with the use of gender-affirming hormonal therapy outside the reference regimen among transgender people in a community-led clinic in Metro Manila, Philippines: a retrospective cross-sectional study.
Eustaquio PC; Dela Cruz JDM; Araña Y; Rosos B; Rosadiño JDT; Pagtakhan RG; Regencia ZJG; Baja ES
BMJ Open; 2023 Sep; 13(9):e072252. PubMed ID: 37669846
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy.
Mullins ES; Geer R; Metcalf M; Piccola J; Lane A; Conard LAE; Mullins TLK
Pediatrics; 2021 Apr; 147(4):. PubMed ID: 33753543
[TBL] [Abstract][Full Text] [Related]
17. New Insights Into Extended Steroid Hormone Profiles in Transwomen in a Multi-Center Setting in Germany.
Schneider F; Wistuba J; Holterhus PM; Kulle A; Schlatt S; Kliesch S; Neuhaus N; Zitzmann M
J Sex Med; 2021 Oct; 18(10):1807-1817. PubMed ID: 34600646
[TBL] [Abstract][Full Text] [Related]
18. Gender-affirming pharmacotherapy and additional health considerations: A contemporary review.
Mercer J; Bandy S; Tang H; Wenger B; Ryan L; Lee G; Lipscomb J
J Am Pharm Assoc (2003); 2023; 63(6):1669-1676.e1. PubMed ID: 37619851
[TBL] [Abstract][Full Text] [Related]
19. Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study.
Glintborg D; Rubin KH; Kristensen SB; Lidegaard Ø; T'Sjoen G; Hilden M; Andersen MS
Andrology; 2022 Jul; 10(5):885-893. PubMed ID: 35366390
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
